FIELD: medicine.
SUBSTANCE: invention relates to immunology and medicine. Disclosed is use of an antibody or antigen-binding fragment thereof, which specifically binds to human delta-like ligand 4 (Dll4), in preventing recurrent multiple sclerosis or reduction of development of a given disease during recurrence thereof in a subject. Also disclosed is use of said antibody or antigen-binding fragment thereof in preparing respective drug.
EFFECT: using antibody or antigen-binding fragment thereof according to present invention provides blocking signaling pathways of Dll4-Notch and increases number of regulatory T-cells.
8 cl, 11 dwg, 8 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING DIABETES WITH DLL4 ANTAGONISTS | 2011 |
|
RU2587624C2 |
| HUMAN ANTIBODIES TO DELTA-LIKE HUMAN LIGAND-4 | 2007 |
|
RU2448979C2 |
| METHOD OF TREATING CANCER WITH DLL4 ANTAGONIST AND CHEMOTHERAPEUTIC AGENT | 2010 |
|
RU2571220C2 |
| HIGH-AFFINITY HUMAN IL-4 RECEPTOR ANTIBODIES | 2007 |
|
RU2445318C2 |
| HUMAN ANTIBODIES WITH HIGH AFFINITY TO HUMAN NERVE GROWTH FACTOR | 2008 |
|
RU2473564C2 |
| HIGH-AFFINITY HUMAN ANGIOPOIETIN-2 ANTIBODIES | 2010 |
|
RU2545399C2 |
| HUMAN ANTIBODIES WITH HIGH AFFINITY TO HUMAN IL-4 RECEPTORS | 2009 |
|
RU2539774C2 |
| HIGH-AFFINITY HUMAN ANTIBODIES TO HUMAN IL-4 RECEPTOR | 2014 |
|
RU2663106C2 |
| THERAPEUTIC DLL4-BINDING PROTEINS | 2011 |
|
RU2605928C2 |
| HUMAN RET-BINDING ANTIBODIES AND METHODS OF USE THEREOF | 2020 |
|
RU2821548C2 |
